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Microorganisms have been extensively used since ancient times for the production of fermented 29 food and beverages, thousands of years before the actual nature of the fermentative processes was 30 known. In the early 20 th century the production of citric acid based on microbial fermentation was 31 initiated as the first large scale fermentation product and this was followed by industrial production 32 of penicillin as the first antibiotic. Introduction of the genetic engineering in the 70's paved the way 33 for the establishment and development of the current biotech industry, allowing the commercial 34 production of industrial enzymes and biopharmaceutical proteins. In 1980, the FDA approved for 35 clinical use the recombinant insulin obtained from E. coli, becoming the first recombinant 36 pharmaceutical protein to enter the market [1] . Since then, the biotechnology industry has grown 37 substantially, and currently about 25% of commercial pharmaceuticals are biopharmaceuticals [2] 38 with 2010 sales exceeding USD100 billions [3] . About half of the world--wide sales are in the USA with 39 monoclonal antibodies representing the majority (>USD18 billions) followed by hormones (USD11 40 billions) and growth factors (>USD10 billions) [4] . Together with the production of industrial enzymes, 41 the recombinant protein production market is expected to rise to 169 billion dollars in 2014 Industrial biotechnology has traditionally used numerous bacterial and eukaryal cells as production 47 platforms, with the main criterion for host selection being the ability to produce the desired 48 compound. However, with the advent of genetic engineering it became possible to introduce 49 heterologous genes and create new traits in non--natural producers, allowing the development of cell 50 factories for the production of chemicals through metabolic engineering. E. coli was the earliest 51 platform to be exploited, and is still nowadays the most used production platform for recombinant 52 proteins [5] , covering approx. 30% of the total production of recombinant proteins [1] (Figure  1 ). In 53 general terms, bacteria have been considered to be the most efficient producers of heterologous 54 proteins due to several reasons: i) well developed molecular tools for genetic manipulation, ii) 55 annotated genomes and metabolic pathways, iii) high cell density cultivation capacity and growth 56 rate and iv) high yield of recombinant proteins, up to 80% of its dry weight [6--8] hybridoma and CHO cells clearly have the highest similarity to human cells, and proteins produced by 68 these systems are often properly folded and glycosylated. However the costs for their cultivation are 69 high (e.g. expensive media and growth factors, contaminations with microorganisms and viruses), 70 they have a limited secretion capacity and protein yields are usually low [15] . On the other hand 71 fungal expression systems, and in particular yeast, can grow in relatively cheap and defined media, 72 decreasing the production costs. Besides, they are not so susceptible to contaminations and in 73 addition, the yeast cells are less sensitive since the wall makes them more resistant to shear stress 74 during the production process [10] . Yeast expression systems also provide higher protein titers 75 (>1g/l) in fermentation processes that even last shorter time (only few days) [16] . Based on this, we 76 propose yeast as an attractive choice, and recent advances in genetic and metabolic engineering, and 77 tools in genomics and systems biology could make S. cerevisiae a preferred production platform for a 78 range of pharmaceutical proteins [17] . However, even though yeasts are eukaryotic systems, the 79 glycosylations of proteins may differ substantially from that performed by mammalian cells, a 80 difference that can be in some cases detrimental for its subsequent therapeutic use. N--glycosylation 81 in yeast, for example, is of the high mannose type whereas human N--glycans are mainly of the 82 complex or hybrid type. In addition to N--glycosylation, yeast O--glycosylation characterized by shorter 83 glycan structures, also differs from the human type, which is mucin--type in contrast to the 84 oligomannosyl--glycans in yeasts [10] . Very promising attempts have been recently achieved to 85 introduce human glycosylation patterns in yeast (humanized yeast platforms). To date, only Pichia 86 species have been successfully engineered to produce specific human--like glycoforms of proteins, 87 however recent advances reported in this field in S. cerevisiae seem to indicate that, with further 88 development, it may increase the array of strains available that are able to produce human--type 89 glycosylated proteins, and these strains will become a valuable platform for the production of 90 glycoproteins for therapeutic use [10, 18, 19] . 91 92
How to make Saccharomyces cerevisiae a better producer of pharmaceutical proteins? 93 94 95
The technology for industrial production of recombinant pharmaceutical proteins in S. cerevisiae is 96 well established and currently applied for production of human insulin, hepatitis virus vaccines and 97 human papilloma virus vaccines, and its potential to be used for large scale production of many other 98 proteins in the forthcoming years is therefore high. Furthermore, the advent of systems biology 99 allowing global metabolism analysis and the application of so--called "omics" approaches such as 100 transcriptome, proteome and metabolome data, facilitates the identification of the bottlenecks and 101 factors limiting the full potential of this yeast to become a better producer [20, 21] , and consequently 102 the application of metabolic engineering to overcome constraints in productivity could definitely 103 allow the establishment of S. cerevisiae as a suitable platform for large scale production of 104 heterologous (including human) proteins [22] . 105 106
There are several reports describing how either genetic or metabolic engineering can be successfully 107 performed in S. cerevisiae [22, 23] resulting in the generation of strains showing an enhanced 108 production capacity of heterologous proteins [17, 24, 25] . Often just introducing an entire new 109 pathway for the production of the desired compound does not result in high levels of production. 110 because protein folding and secretion can represent the major limitation in terms of protein yields in 111 yeast [20] . Folding and secretion are complex processes and the molecular machineries are 112 composed of large number of components, so further modifications and development of these 113 pathways requires integrative analysis of the whole secretory pathway. Such approach has been 114 successfully carried out by engineering different elements of the secretory pathway, and by 115 combining different expression systems in order to optimize the production of several kinds of 116 different proteins showing different biochemical properties (i.e. size, type of modification 117 (glycosylation and/or disulfide bond formation)), such as human insulin precursor or α--amylase 118 [17, 26, 27] . Through a combination of these approaches it is possible to select the best protein 119 producers for further optimization, and this may lead to generic protein producing strains that can be 120 used as general platforms for the production of bio--based pharmaceutical proteins (Figure 2 ). 121 usually quite high, normally over 10g/L, many studies have tried to express rHSA also in P. pastoris 133 for its high capacity in heterologous protein production [30] . The rHSA produced from P. pastoris has 134 gone through the clinical trials and confirmed the safety and efficacy to treat different diseases [31] . 135 136
Production of Recombinant Human Blood Proteins
Aside from rHSA, many other human blood proteins are also under active studies [32--34] . Human 137 fibrinogen (Hf) is a large plasma glycoprotein that plays a critical role in the last stage of coagulation. 138
It is dimeric and comprised of two sets of three different polypeptides, namely Aα, Bβ and γ. The 139 protein was expressed in P. pastoris protease deficient strain by constructing an expression vector 140 containing the cDNA of three individual peptide chains. Even though the peptides expressed were of 141 different N--glycosylation patterns as that of native Hf, they were correctly assembled to a functional 142 rHf that is capable of forming a clot in the presence of factor XIIIa [32] . Human α--1--antitrypsin 143 (hAAT) was produced in tomato: the codon modified cDNA sequence was expressed and the mRNA 144 5' and 3' flanking regions were modified to achieve a high--level expression by eliminating mRNA 145 destabilizing sequences, which are ATTTA and its variants, splice sites and A/T strings. In contrast to 146 the unglycosylated rAAT expressed in E. coli, the glycosylated rATT from transgenic tomato was 147 biologically active [33] . One more example is the production of human transferrins (Tf) which are a 148 family of monomeric proteins that are of different sizes depending on the extent of glycosylation. 149
Besides its central role to facilitate iron transport and metabolism, a lot more other functions have 150 been evidenced, e.g. acting as a growth factor for mammalian tissue cells, as a neurotropic factor 151 during neural stem cell development and as an angiogenic factor to promote endothelial cell 152 migration etc, enabling a development of many novel practical applications in medicine [34] . To date, 153 several heterologous systems including E. coli, yeast, transgenic plants, mammalian and insect cells 154 have been developed for rhTf production [34] , among which E. coli was reported to be inefficient due 155 to the production of inactive hTf. Successful expressions of hTf were reported in S.cerevisiae and P. The previous examples and the state--of--the--art methodologies and approaches show that S. 186 cerevisiae can be engineered to become an even better producer for a wider range of 187 pharmaceutical and blood proteins. Comparing to E. coli, heterologous proteins produced in S. 188 cerevisiae do not have methionine modification which affecting the biological function of the rHb. 189
Compared to plant and animal expression systems, the yeast system is cheaper and faster to 190 manipulate. As an outlook, we propose several potential strategies for increasing human hemoglobin 191 production in S. cerevisiae e.g. globin folding, heme uptake, and subunit assembling. 
